With the mission to tackle the massive oncology dilemma, Elephas is leading the way to change how clinicians treat cancer patients. By harnessing the latest advances in cancer biology, multimodal microscopy, and artificial intelligence, the Elephas platform has the ability to empower clinical decision making and accelerate drug development. We plan to use the power of our platform to deliver a global solution that can revolutionize cancer treatment for every individual. To learn more, visit us at and follow us on LinkedIn. XMS Capital Partners acted as financial advisor to the company.ĪRCH Venture Partners’ Paul Berns will join the Elephas board of directors and ARCH’s Keith Crandell will be joining as a board observer. This follows the recent appointment by the company of Steven Galson, the former director of the Center for Drug Evaluation and Research at FDA, as independent director.ĭisruption in healthcare is being accelerated by the need for improved diagnostics, novel pharmaceutical therapies, and the shift to patient-centric solutions. “We are excited to partner with the company to bring this novel solution to patients.” “Technology that will allow patients to receive the most effective therapy quickly, before time and resources are spent on ineffective options, will change the game for those diagnosed with cancer,” ARCH Venture Partners’ Paul Berns added. “We are grateful for the support of these world-class venture firms who believe in what we are doing and are committed to helping us get there.” “Our mission at Elephas is to improve care for cancer patients,” stated Maneesh Arora, founder and CEO of Elephas. Oncology drugs remain the largest pharmaceutical therapeutic area, with immunotherapies emerging in the last decade as effective and powerful tools in the fight against cancer. The company also plans to make the platform available to biopharma researchers next year. The latest advances in cancer biology combined with multi-modal imaging are used to assess how patients will respond before beginning treatment.Įlephas is launching two human clinical trials on the platform in the next quarter and plans to share initial clinical data in 2023.
#Arch venture partners series#
Prior investments include $20 million from the Series A and $8 million from the founder and early seed investors.Įlephas is developing an oncology diagnostics platform to predict response to immunotherapy. The platform utilizes live fragments from a patient biopsy and treats those fragments with potential therapies and combinations. Continuing investments were made by Northpond Ventures, Sands Capital, and WARF Ventures. ARCH Venture Partners led the round, and were joined by new investors, Moore Strategic Ventures and Tao Capital Partners. Elephas Biosciences Corporation (Elephas), a private company, announced today that it has raised $41.5 million in Series B funding. Elephas Announces $41.5 Million in Series B FundingĪRCH Venture Partners leads round to advance company’s novel live tumor diagnostic platform
0 kommentar(er)
